secwatch.observer — SEC 8-K summary
======================================

Issuer:     Renalytix plc (RNLXY)
CIK:        0001811115
Form:       8-K
Filed at:   2024-04-23T23:59:59+00:00
Accession:  0000950170-24-047020
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Renalytix president McLain resigns, Howard Doran appointed; equity offering expanded
--------------------------------------------------------------------------------

- Thomas McLain resigns as President effective April 30, 2024; severance includes 6 months base salary ($450K) and accelerated vesting of 12 months of options.
- Howard Doran appointed President effective April 30, 2024; base salary increased to $350K from $300K.
- Investor DB Capital exercised option to buy 1,333,334 additional shares at $0.375/share, raising net ~$0.5M.
- Shareholders approved allotment of up to 26.8M new ordinary shares and related pre-emptive waivers with >98% support.
- Original option exercise period extended to April 22, 2024 via letter agreement; total offering includes 4M shares at $0.375.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811115/000095017024047020/0000950170-24-047020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811115/000095017024047020/rnlx-20240417.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-047020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer